TABLE 4.
Cox regression analysis of the clinical outcomes in HCC patients based on various clinicopathological characteristics including EXO1 levels.
| Characteristics | HR for overall survival (95% CI) | HR for disease-specific survival (95% CI) | HR for progression-free interval (95% CI) | |||
|---|---|---|---|---|---|---|
| Univariate | Multivariate | Univariate | Multivariate | Univariate | Multivariate | |
| Race (Asian vs. White) | 1.324 | 1.544 | 0.983 | 1.280 | ||
| T stage (T1 vs. T2&T3&T4) | 2.126*** | 1.229 | 2.829*** | 1.229 | 2.360*** | 1.508* |
| Pathologic stage (Stage I and II vs. Stage III and IV) | 2.504*** | 1.776* | 3.803*** | 2.900** | 2.201*** | 1.292 |
| Tumor status (Tumor free vs. With tumor) | 2.317*** | 1.723** | 775790759.389 | 11.342*** | 10.602*** | |
| Histologic grade (G1&G2 vs. G3&G4) | 1.091 | 1.086 | 1.152 | |||
| AFP (ng/ml) (≤400 vs.> 400) | 1.075 | 0.867 | 1.045 | |||
| EXO1 (Low vs. High) | 2.036*** | 1.684** | 2.564*** | 2.216** | 1.678*** | 1.200 |
HCC, hepatocellular carcinoma; HR, hazard ratio; CI, confidence interval; AFP, alpha-fetoprotein; *p < 0.05; **p < 0.01; ***p < 0.001.